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Abstract - The function of peroxisome proliferator-activated receptor γ (PPARγ) in immune regulation, as well as in anti-
inflammatory and anti-proliferative actions towards T lymphocytes, has been reported. A potential role of PPARs in mul-
tiple sclerosis (MS) was suggested. The aim of this study was to investigate if there is an association of PPARγ-2 Pro12Ala 
polymorphism with MS in 361 patients from Serbia. The genotype and allele frequencies of Pro12Ala polymorphism 
were not significantly different between controls and patients, or between females and males. In contrast to controls, we 
detected a rare Ala/Ala genotype in patients with MS. We found that there is a significant association of Ala/Ala genotype 
with older age at onset (ANOVA, p=0.07; LSD post-hoc, Ala/Ala vs. Pro/Ala, p=0.03, Ala/Ala vs. Pro/Pro p=0.02). It would 
be useful to validate our results in other populations, as well as to perform follow-up of the disease progression in regard 
to PPARγ genotypes.  
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INTRODUCTION
Multiple sclerosis (MS) is a polygene prototype in-
flammatory autoimmune disorder of the central 
nervous system (CNS) (Compston et al., 2002). The 
etiology of the disease is not completely understood, 
but it has been proposed that the MS phenotype re-
sults from the interaction of genetic makeup and en-
vironmental factors. 
Peroxisome proliferator-activated receptors 
(PPARs) are members of the nuclear receptor su-
perfamily, and they function as gene regulators in a 
ligand-dependent manner. We can distinguish three 
subtypes of PPAR – PPARα, PPARβ and PPARγ, 
which are encoded by different genes. The function 
of PPARγ was primarily described in the context 
of glucose and lipid metabolism (Desvergne et al., 
1999). Apart from its role in metabolism, an impor-
tant function of PPARγ in immune regulation has 
been reported (Glass et al., 2006). The role of PPARγ 
in anti-inflammatory and anti-proliferative actions 
towards T lymphocytes had been shown previ-
ously (Schmidt et al., 2004). Recently, emphasis was 
placed on their function as inhibitors of the TH17 
lymphocyte subset (Klotz et al., 2009a). The effects 
of PPARγ were also studied in experimental allergic 
encephalomyelitis (EAE), an animal model for MS. 
It has been reported that a heterozygous PPARγ-
deficient mouse exhibits an exacerbated MS phe-
notype accompanied by increased T-cell expansion 
and pronounced immune responses (Natarajan et al., 
2003). It was also shown that the activation of PPARγ 
by specific agonists reduces symptoms of EAE (Fein-
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stein et al., 2002). This demonstrated the importance 
of PPARγ in the regulation of CNS autoimmunity, 
emphasizing the role of this family of transcription 
factors in limiting the progression and prevention of 
autoimmune diseases of the CNS. 
The PPARγ gene is located on chromosome 
3p25.2 (Greene et al., 1995; Beamer et al., 1997). It 
gives rise to four alternative splicing transcripts (γ1, 
γ2, γ3 and γ4), which are transcribed from four dif-
ferent promoters and differ in their first exons. All 
of the transcripts yield the same protein, except for 
the γ2 transcript which encodes for 30 additional 
amino acids on the N-terminus (Ackert-Bicknell et 
al., 2006). The PPARγ1 variant is widely expressed 
while PPARγ2 is expressed specifically in adipose tis-
sue (Tontonoz et al., 1994).
The Pro12Ala substitution in the PPARγ2 gene 
was originally described by Yen et al. (Yen et al., 
1997). This is a CCA-to-GCA missense mutation 
located in codon 12 of exon 1, the region of the gene 
that codes the domain which enhances ligand-inde-
pendent activation (Werman et al., 1997). Pro12Ala 
exchange results in reduced transcriptional activity 
(Deeb et al., 1998) and diminished binding efficien-
cy toward PPAR responsive elements (PPRE) (Mas-
ugi et al., 2000). This polymorphism was previously 
extensively studied in association with phenotypes 
such as diabetes mellitus type 2 and metabolic syn-
drome.
The potential role of PPARs in MS has been sug-
gested but after a thorough search through the litera-
ture and existing databases with the results of MS ge-
netic studies (http://www.msgene.org, http://t1dbase.
org), we found that only one study had been under-
taken to assess the association of PPARγ-2 Pro12Ala 
(rs1801282) polymorphism with MS (Klotz et al., 
2009b). The aim of this work was to perform a sec-
ond, larger study in patients with multiple sclerosis 
from Serbia. 
ANOVA, p=0.07; LSD post-hoc, * Ala/Ala vs. Pro/Ala, p=0.03, # Ala/Ala vs. Pro/Pro p=0.02
Fig. 1. PPARγ Pro12Ala genotypes and age at onset of MS
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MATERIALS AND METHODS
Subjects
Three hundred and sixty one (n=361) unrelated pa-
tient with relapsing-remitting (RR) and secondary 
progressive (SP) multiple sclerosis of Serbian ori-
gin were recruited from the Neurology Clinic of the 
Military Medical Academy (MMA), Serbia. All pa-
tients fulfilled the criteria for clinically definite MS 
(Polman et al., 2011) and the course of the disease 
was determined according to the clinical data (Lub-
lin et al., 1996). Disease severity was estimated in ac-
cordance with the Multiple Sclerosis Severity Score 
(MSSS) (Roxburgh et al., 2005), representing the Ex-
panded Disability Status Scale (EDSS) (Kurtzke et al., 
1883) corrected for disease duration. Global MSSS 
values were calculated according to the clinical data 
at the time when the blood samples for genetic anal-
ysis were taken. The patients were not undergoing 
immunomodulatory treatment at the time of MSSS 
estimation. 
The MS patients group consisted of 60.4% fe-
males and 39.6% males. The female-to-male ra-
tio was 1.5. The mean age in the patient group was 
38.5±10.5 years, while the mean age at disease onset 
was 30.0±8.9 years. The control group consisted of 
103 healthy female and 90 male volunteers, members 
of the MMA staff, aged 40.3±14.2 and of the same 
ethnic origin as the MS patients. The Ethical Com-
mittee of the MMA approved the study. Each partici-
pant gave written informed consent to participate in 
the study.  
Genetic analysis
Genomic DNA was isolated from peripheral blood 
samples collected with EDTA and purified by the 
proteinase K/phenol extraction method (Kunkel et 
al., 1997). 
The Pro12Ala polymorphism was analyzed by 
PCR using an ABI 2700 Thermal cycler (Applied Bi-
osystems, Foster City, CA). The sequences of primers 
were 5’-TCTGGGAGATTCTCCTATTGGC–3’ (for-
ward primer) and 5’–CTGGAAGACAAACTACAA-
GAG–3’ (reverse primer) (Hara et al., 2000). The 
forward primer contained one nucleotide mismatch, 
making it possible to use the restriction enzyme 
Hin6I for the detection of Pro12Ala polymorphism. 
The PCR reaction was carried out in a 25 μl reac-
tion mixture containing 200 ng of genomic DNA, 
0.15 μM of each primer, 200 μM of each dNTP (Fer-
mentas, Lithuania) and 1U of DreamTaq polymerase 
(Fermentas, Lithuania). The reaction mixtures were 
incubated at 95oC for 5 min, followed by 35 cycles of 
denaturation at 94oC for 30 s, annealing at 52oC for 
30 s and extension at 72oC for 30 s. The PCR prod-
ucts were digested with Hin6I at 37oC overnight. The 
Pro allele gave one 154 bp fragment, whereas the Ala 
allele gave 133 bp and 21 bp fragments. The digestion 
products were loaded onto an 8% polyacrylamide gel 
for genotyping and run for 2 h in an electric field of 
12 V/cm. The gels were stained with silver nitrate 
and visualized using a GDS8000 gel documentation 
system (Ultra Violet Products, Inc., Upland).
Statistical analysis
Statistical analysis was performed using Statistica 
software package version 5 (Stat Soft Inc., 1997). Es-
timation of differences in the distribution of both al-
lele and genotype frequencies between control and 
patient groups, as well as deviation from the Hardy-
Weinberg equilibrium, were performed by the Pear-
son chi-square (χ2) test. For an analysis of the effects 
of genotype on descriptive and clinical parameters, 
such as age at onset, disease duration and MSSS val-
ues, we used the analysis of variance (ANOVA) fol-
lowed by a post-hoc test. Differences with two-tailed 
alpha probability (p) < 0.05 were considered signifi-
cant in all tests.
RESULTS
Patients
The 218 female and 143 male patients with clini-
cally definite MS were included in this study (72.3% 
of RR with disease duration of 7.4±5.7 years and 
28.7% of the SP patients with disease duration of 
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14.7±7.3). The mean age in the patient group was 
38.5±10.5 years, while the mean age at disease onset 
was 30.0±8.9 years. The mean MSSS in all patients 
was 4.5±2.2 (in the RR group it was 4.1±2.2, while in 
the SP group it was 6.5±2.5). We deliberately selected 
subjects in the control group who were not younger 
than the patients so that the possibility of younger, 
healthy subjects to develop MS in the future would 
be minimal. 
Genotypes and alleles in MS patients and controls
The prevalence of Pro12Ala polymorphism of the 
PPARγ-2 gene in MS patients and controls is shown 
in Table 1. We did not find any deviations from 
Hardy-Wainberg equilibrium, either in the control 
group or among the patients. The genotype and allele 
frequencies of Pro12Ala polymorphism were not sig-
nificantly different between the control subjects and 
the patients (Table 1). We also checked for the geno-
type distribution according to gender, and found no 
difference in females compared to the males, or in 
female and male patients compared to the controls 
of the same gender.
Genotypes and clinical parameters
We analyzed the possible association of Pro12Ala 
genotypes with disease course, age at onset and 
MSSS. The genotype distribution was not signifi-
cantly different between RR and SP patients (76.7%, 
22.5%, 0.8% vs. 76.2%, 23.8%, 0%, respectively). 
There was no association of genotypes with MSSS 
(data not shown). We found a significant association 
of the Ala/Ala genotype with an older age at onset 
(ANOVA, p=0.07; LSD post-hoc, Ala/Ala vs. Pro/
Ala, p=0.03, Ala/Ala vs. Pro/Pro p=0.02, (Fig. 1)). 
All patients with Ala/Ala genotype were in the RR 
group, with mean disease duration of 3.0±2.8 years 
(not significantly different from other genotypes).
DISCUSSION
The present study examined PPARγ-2 Pro12Ala 
gene polymorphism as a potential risk factor for MS. 
We did not find an association of Pro12Ala polymor-
phism with susceptibility to multiple sclerosis. It was 
previously suggested that there is a north-to-south 
gradient in the frequency of the 12Ala allele, as well 
as the heterogeneity of its effect on DMT2, accord-
ing to the same gradient. The effect size tended to be 
lower in the south (Ludovico et al., 2007). Similarly, 
one of the most striking epidemiological character-
istics of MS is the uneven distribution of the disease 
worldwide, which means decreasing prevalence in a 
north-to-south gradient in the northern hemisphere. 
The 12Ala allele frequency in the healthy participants 
of the Serbian population is in the same range as in 
Table 1. Genotype and allele frequencies of PPAR gamma Pro12Ala polymorphism in MS patients and controls
Genotype Overall Females Males
Controls
n=193 (%)
MS
n=361 (%) p (χ
2) Controlsn=103 (%)
MS
n=218 (%) p(χ
2) Controlsn=90 (%)
MS
n=143 (%) p(χ
2)
Pro12Pro 155 (80.3) 275 (76.1) 0.31 81 (79.4) 166 (76.2) 0.51 74 (82.2) 109 (76.2) 0.32
Pro12Ala 38 (19.7) 84 (23.3) 22 (21.6) 50 (22.9) 16 (17.8) 34 (23.8)
Ala 12Ala 0 (0.0) 2 (0.6) 0 (0.0) 2 (0.9) 0 (0.0) 0 (0.0)
Allele
Pro12 0.90 0.88 ns 0.89 0.88 ns 0.91 0.88 ns
Ala12 0.10 0.12 0.11 0.12 0.09 0.12
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other Caucasians, and follows the north-to-south 
gradient, with 12Ala frequency similar to the Italian 
population (Scacchi et al., 2007), significantly lower 
compared to the Finnish, Swedish and Danish popu-
lations (Altshuler et al., 2000; Hansen et al., 2005). 
As within the controls, we found slightly lower 12Ala 
frequency among patients with multiple sclerosis 
compared to the sole previous study in the German 
population (0.12 vs. 0.15, respectively) (Klotz et al., 
2009b). Nonetheless, an important finding is that we 
did not find any subject homozygous for 12Ala, ei-
ther in the control population or in T2DM patients 
from Serbia (Soskic et al., 2010); in the MS patients 
we found 0.6%. Nevertheless, neither we nor the au-
thors of the previous study (Klotz et al., 2009b) have 
found significant association of this polymorphism 
with MS susceptibility.
The main and only significant finding in our 
study was the association of the Ala/Ala genotype 
with an older age at MS onset in comparison to 
genotypes that carry the Pro12 allele. This result is 
in complete accordance with the previous study of 
PPARγ-2 Pro12Ala polymorphism with MS, which 
also showed significantly later disease onset in Ala/
Ala genotype in a population of German patients 
with MS (Klotz et al., 2009b). Although the Ala/Ala 
homozygote is very rare in a population and in both 
studies of MS, the difference in age at onset was sig-
nificant and reproducible. It is reasonable to assume 
that if there is an effect of the PPARγ gene on MS, it 
is at the level of disease modulation rather than in 
disease susceptibility.
It had been proven that the presence of pro-in-
flammatory cytokines (a state that is similar to the 
state of relapse in MS) causes a reduction of PPARγ-2 
expression in mouse adipocytes (Tanaka et al., 1999), 
and reduces the expression levels of PPARγ in pe-
ripheral blood mononuclear cells taken from MS 
patients (Klotz et al., 2005). Transient transfection 
assays demonstrate that the Ala-variant exhibited al-
tered the binding activity to PPARγ-responsive DNA 
elements, as compared to the wild type of PPARγ 
(Deeb et al., 1998; Masugi et al., 2000). It was also sug-
gested that the Ala/Ala genotype could be involved 
in a protection from the inflammation-induced loss 
of PPARγ, thus favoring the balance towards anti-
inflammatory signaling (Klotz et al., 2009b). So far, 
without further follow-up of the patients with Ala/
Ala genotype, we cannot discuss whether there is an 
influence on disease severity and its course. It would 
be interesting to carry out such research, since there 
is a short disease duration (3±2.8) and the patients 
are still in the RR phase. Of course, a higher number 
of patients should be involved in the follow-up, but 
only if the study were of a multicenter kind, because 
the Ala/Ala is rare.
In current pharmacogenomic research of in-
flammatory related diseases such as MS, PPARγ has 
a very important role (Drew et al., 2008). Treatment 
with PPARγ agonists was observed to have protec-
tive effects in a mouse model of neuroinflammation 
(Jeongl et al., 2011). Also, it was shown that the pros-
tanoid PGD2 dehydration product 15-deoxy –Δ12, 14 
15d-PGJ2, a ligand for PPARγ (Forman et al., 1995; 
Kliewer et al., 1995), mediates immunological re-
sponse by reducing inflammatory response (Clark 
et al., 2000). An in vitro study which directly dealt 
with MS, proved that the synthetic PPARγ ligand 
pioglitazone, the investigational drug GW347845 
and ciglitazon, inhibit the proliferation and secre-
tion of pro-inflammatory cytokines of peripheral 
blood mononuclear cells derived from MS patients 
(Schmidt et al., 2004). It was recently proposed to 
use the PPARγ-mediated T cell-intrinsic molecular 
mechanism that selectively controls Th17 differentia-
tion in mice and in humans. The authors suggested 
that it is amenable to pharmacologic modulation and 
thus concluded that PPARγ represents a promising 
molecular target for specific immunointervention 
in Th17-mediated autoimmune diseases such as MS 
(Klotz et al., 2009a).
Nevertheless, we can conclude that we replicated 
the significant association of Ala/Ala genotype with 
delayed MS onset in a specific southeastern Euro-
pean population. As literature data supports the idea 
that PPARγ has a role in neuroinflammation and in 
MS, it would be worthwhile to validate our results 
in other populations, especially in those with high-
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er frequency of 12Ala allele, as well as to perform 
multicentric follow-up of the disease progression in 
regard to PPARγ genotypes in order to address this 
question.
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